A cooderative studv on proMACE-dytaBOM in aggressive non-hodgkin's lymphomas

Edmondo Cassi, Chiara Butti, Luca Baldini, Gaetano Brambilla Pisoni, Anna Ceriani, Carlo Confalonieri, Luciano Scandolaro, Alberto De Paoli, Franco Lombardi, Luigi Montalbetti, Ruggero Mozzana, Gianfranco Pavia, Graziella Pinotti, Pietro Pioltelli, Enrico Pogliani, Anna Tosi, Paolo Vanoli, Giorgio Lambertenghi-Deliliers

Research output: Contribution to journalArticlepeer-review


Chemotherapy using cyclophosphamide, doxorubicin, etoposide, cytarabine, bleomycin, vin-cristine, methotrexate with leucovorin, and prednisone (ProMACE-CytaBOM) for patients with intermediate or high grade non-Hodgkin lymphomas (G, H and K according to the Working Formulation), was tested by the Gruppo Cooperativo Lombardo to confirm the activity of the regimen and to test the feasibility and safety of administering third-generation drug regimen in a cooperative group setting. Among 64 previously untreated patients, aged between 20 and 71 years, 7 had stage IB-IIB, 12 had stage IIIA-B, 45 (67% had stage IV A-B. There were 44 complete remissions (CRs) (69% and 14 partial remissions (22%; the difference between patients in stage 1-11-111 (84% complete remissions) and those in stage IV (62% complete remissions) was statistically significant. The median length of follow up was 20 months (range 1-60 months), with 56% of patients alive at 60 months and 53% of CRs patients free of disease at 60 months. Patients in stage 1-11-111 have the best survival and disease free survival compared to stage IV, 87% versus 42% and 72% versus 32% respectively (both with high statistical significance). Grade 3-4 (WHO) haematological toxicity was observed in 39% of patients, with 3 septic deaths. Two more patients died with chemotherapy related toxicity (1 stroke and 1 acute renal insufficiency). Administration of ProMACE-Cyta BOM is a feasible and safe regimen although it presents moderate toxicity. ProMACE-CytaBOM may represent improved treatment for aggressive lymphomas, in terms of duration of response and survival, but a longer follow up is needed.

Original languageEnglish
Pages (from-to)111-118
Number of pages8
JournalLeukemia and Lymphoma
Issue number1-2
Publication statusPublished - 1994


  • Aggressive lymphoma
  • Chemotherapy
  • Non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology


Dive into the research topics of 'A cooderative studv on proMACE-dytaBOM in aggressive non-hodgkin's lymphomas'. Together they form a unique fingerprint.

Cite this